Zhejiang Hisoar Pharmaceutical Co., Ltd.

Symbol: 002099.SZ

SHZ

6.33

CNY

Market price today

  • -24.3560

    P/E Ratio

  • -0.1402

    PEG Ratio

  • 10.05B

    MRK Cap

  • 0.01%

    DIV Yield

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.17%

Operating Profit Margin

-0.23%

Net Profit Margin

-0.21%

Return on Assets

-0.06%

Return on Equity

-0.07%

Return on Capital Employed

-0.08%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Guorui Xu
Full-time employees:2612
City:Taizhou
Address:No. 100, Waisha Branch Road
IPO:2006-12-26
CIK:

Zhejiang Hisoar Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells fine chemicals and special raw drugs in China and internationally. It offers antibiotic, anti-virus, cardiovascular, sugar-reducing, and other materials; and medicine intermediates, and other customized and processed products, such as clindamycin, 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, voglibose, eclindamycin, 4-AA iso-carbapenem, thiamphenicol, florfenicol, voglibose, etc. It also exports its products. The company was founded in 1966 and is based in Taizhou, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.167% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.232%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.208%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.056% return, is a testament to Zhejiang Hisoar Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Zhejiang Hisoar Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.074%. Furthermore, the proficiency of Zhejiang Hisoar Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable -0.083% return on capital employed.

Stock Prices

Zhejiang Hisoar Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.16, while its low point bottomed out at $5.67. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Zhejiang Hisoar Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 002099.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 148.50% gauges short-term asset coverage for liabilities. The quick ratio (138.70%) assesses immediate liquidity, while the cash ratio (84.14%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio148.50%
Quick Ratio138.70%
Cash Ratio84.14%

Profitability Ratios

002099.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -23.25% underscores its earnings before tax deductions. The effective tax rate stands at 10.23%, revealing its tax efficiency. The net income per EBT, 89.41%, and the EBT per EBIT, 100.19%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -23.21%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-23.25%
Effective Tax Rate10.23%
Net Income per EBT89.41%
EBT per EBIT100.19%
EBIT per Revenue-23.21%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.49, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 373.18% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding139
Days of Inventory Outstanding135
Operating Cycle232.67
Days of Payables Outstanding117
Cash Conversion Cycle115
Receivables Turnover3.73
Payables Turnover3.11
Inventory Turnover2.71
Fixed Asset Turnover0.69
Asset Turnover0.27

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.05, and free cash flow per share, -0.04, depict cash generation on a per-share basis. The cash per share value, 1.27, showcases liquidity position. A payout ratio of -0.28 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.04, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.05
Free Cash Flow per Share-0.04
Cash per Share1.27
Payout Ratio-0.28
Operating Cash Flow Sales Ratio0.04
Free Cash Flow to Operating Cash Flow Ratio-0.67
Cash Flow Coverage Ratio0.06
Short Term Coverage Ratio0.07
Capital Expenditure Coverage Ratio0.60
Dividend Paid and Capex Coverage Ratio0.32
Dividend Payout Ratio0.01

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 17.51%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.24, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.12%, and total debt to capitalization, 19.47%, ratios shed light on its capital structure. An interest coverage of -11.15 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio17.51%
Debt Equity Ratio0.24
Long Term Debt to Capitalization2.12%
Total Debt to Capitalization19.47%
Interest Coverage-11.15
Cash Flow to Debt Ratio0.06
Company Equity Multiplier1.38

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.34, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.26, reflects the portion of profit attributed to each share. The book value per share, 3.47, represents the net asset value distributed per share, while the tangible book value per share, 2.77, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.34
Net Income Per Share-0.26
Book Value Per Share3.47
Tangible Book Value Per Share2.77
Shareholders Equity Per Share3.47
Interest Debt Per Share0.68
Capex Per Share-0.09

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -19.68%, indicates top-line expansion, while the gross profit growth, -57.70%, reveals profitability trends. EBIT growth, -293.12%, and operating income growth, -293.12%, offer insights into operational profitability progression. The net income growth, -577.26%, showcases bottom-line expansion, and the EPS growth, -577.94%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-19.68%
Gross Profit Growth-57.70%
EBIT Growth-293.12%
Operating Income Growth-293.12%
Net Income Growth-577.26%
EPS Growth-577.94%
EPS Diluted Growth-577.94%
Weighted Average Shares Growth-0.19%
Weighted Average Shares Diluted Growth-0.19%
Dividends per Share Growth-39.03%
Operating Cash Flow Growth107.19%
Free Cash Flow Growth238.10%
10-Year Revenue Growth per Share-23.92%
5-Year Revenue Growth per Share-21.27%
3-Year Revenue Growth per Share-11.95%
10-Year Operating CF Growth per Share60.71%
5-Year Operating CF Growth per Share-70.05%
3-Year Operating CF Growth per Share-54.86%
10-Year Net Income Growth per Share-108.00%
5-Year Net Income Growth per Share-168.42%
3-Year Net Income Growth per Share-231.64%
10-Year Shareholders Equity Growth per Share265.81%
5-Year Shareholders Equity Growth per Share2.49%
3-Year Shareholders Equity Growth per Share-4.01%
10-Year Dividend per Share Growth per Share-5.89%
5-Year Dividend per Share Growth per Share-42.70%
3-Year Dividend per Share Growth per Share-75.07%
Receivables Growth-23.64%
Inventory Growth-36.30%
Asset Growth-10.40%
Book Value per Share Growth-8.04%
Debt Growth5.30%
R&D Expense Growth-22.18%
SGA Expenses Growth3.62%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 11,249,106,600.07, captures the company's total value, considering both debt and equity. Income quality, -0.57, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.05, gauges operational efficiency, while the research and development to revenue, 5.32%, highlights investment in innovation. The ratio of intangibles to total assets, 14.95%, indicates the value of non-physical assets, and capex to operating cash flow, -63.64%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value11,249,106,600.07
Income Quality-0.57
Sales General and Administrative to Revenue0.05
Research and Development to Revenue5.32%
Intangibles to Total Assets14.95%
Capex to Operating Cash Flow-63.64%
Capex to Revenue-7.05%
Capex to Depreciation-41.99%
Graham Number4.51
Return on Tangible Assets-6.57%
Graham Net Net0.12
Working Capital818,906,428
Tangible Asset Value4,477,610,541
Net Current Asset Value707,362,584
Average Receivables551,681,914
Average Payables799,190,375
Average Inventory902,356,361.5
Days Sales Outstanding80
Days Payables Outstanding118
Days of Inventory On Hand137
ROIC-6.30%
ROE-0.07%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.89, and the price to book ratio, 1.89, reflect the market's valuation relative to the company's book value. The price to sales ratio, 4.93, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -177.01, and price to operating cash flows, 122.55, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.89
Price to Book Ratio1.89
Price to Sales Ratio4.93
Price Cash Flow Ratio122.55
Price Earnings to Growth Ratio-0.14
Enterprise Value Multiple-136.99
Price Fair Value1.89
Price to Operating Cash Flow Ratio122.55
Price to Free Cash Flows Ratio-177.01
Price to Tangible Book Ratio2.07
Enterprise Value to Sales5.18
Enterprise Value Over EBITDA50.76
EV to Operating Cash Flow46.77
Earnings Yield-3.62%
Free Cash Flow Yield0.75%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -24.356 in 2024.

What is the ticker symbol of Zhejiang Hisoar Pharmaceutical Co., Ltd. stock?

The ticker symbol of Zhejiang Hisoar Pharmaceutical Co., Ltd. stock is 002099.SZ.

What is company IPO date?

IPO date of Zhejiang Hisoar Pharmaceutical Co., Ltd. is 2006-12-26.

What is company current share price?

Current share price is 6.330 CNY.

What is stock market cap today?

The market cap of stock today is 10046249329.000.

What is PEG ratio in 2024?

The current -0.140 is -0.140 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2612.